Clinical Trials Logo

BCC - Basal Cell Carcinoma clinical trials

View clinical trials related to BCC - Basal Cell Carcinoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT06279143 Recruiting - Skin Diseases Clinical Trials

The Diagnostic Accuracy of Advanced Imaging in Identifying Suspected Skin Cancer (Basal Cell Carcinoma) Around the Eyes

dOCT-pBCC
Start date: April 4, 2024
Phase:
Study type: Observational

The purpose is to investigate the diagnostic value (sensitivity and specificity) of dermal-Optical Coherence Tomography (D-OCT, VivoSight Dx), in patients with clinically suspected BCC lesions inside the periocular region and compare these results to previous reports using D-OCT in diagnosing lesions outside the periocular area. The Hypotheses: - The sensitivity and specificity of D-OCT in diagnosing BCC inside the periocular region is comparable to previous reports on BCC lesions outside the periocular region when the standard D-OCT probe is used. - The sensitivity and specificity of D-OCT in diagnosing BCC inside the periocular region is increased when the customised D-OCT probe is used. - The sensitivity and specificity of D-OCT in diagnosing periocular BCC is comparable to punch biopsy when both standard and the customised D-OCT probes are used. - D-OCT with the 10 and 20-millimeter standoff is capable of subtyping periocular BCC. - The inter-observer variation in diagnosing and sub-typing periocular BCC decreases with increasing experience in the scanning procedure. - The number of scans to correctly interpret D-OCT decreases with increasing experience in the scanning procedure. - Delineation of periocular BCC tumour extension is possible using both D-OCT probes

NCT ID: NCT05859074 Recruiting - Melanoma Clinical Trials

A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer

Start date: May 4, 2023
Phase: Phase 1
Study type: Interventional

Participants of this study will have a diagnosis of a solid tumor cancer that has come back to its original location or spread beyond its original location (advanced), came back (relapsed) or worsened (refractory) after standard treatments, or no standard treatments are available for the participants' cancer. The purpose of this study if to find the highest dose of MQ710 that causes few or mild side effects in participants with a solid tumor cancer diagnosis.

NCT ID: NCT05329792 Recruiting - Clinical trials for Merkel Cell Carcinoma

L19IL2/L19TNF in Skin Cancer Patients

IntriNSiC
Start date: March 9, 2023
Phase: Phase 2
Study type: Interventional

Phase II, open label, multicentric, proof-of-principle basket trial in patients with malignant tumors of the skin amenable to intratumoral injection, and in a curative or neoadjuvant or palliative intention.

NCT ID: NCT04918381 Completed - Clinical trials for BCC - Basal Cell Carcinoma

CellFX Treat & Resect Low-Risk BCC Feasibility Study

Start date: June 2, 2021
Phase: N/A
Study type: Interventional

This prospective, multicenter, study is designed to evaluate the safety and effectiveness of the CellFX System in adults subjects with low-risk basal cell carcinoma (superficial and nodular) for complete histological clearance of the target lesion followed by surgical tumor excision 60 days post-treatment.

NCT ID: NCT04570683 Recruiting - Immunotherapy Clinical Trials

Laser Immunotherapy With and Without Topical Anti-PD1 in Basal Cell Carcinomas

Start date: January 27, 2020
Phase: Early Phase 1
Study type: Interventional

The study aim is to assess the immunological and clinical response in basal cell carcinoma (BCC) treated with ablative fractionated laser (AFL) as monotherapy and compare with BCC treated with combination-therapy of AFL and the anti-PD1-drug nivolumab and with nivolumab as monotherapy.

NCT ID: NCT04552990 Active, not recruiting - Clinical trials for Basal Cell Carcinoma

Use of Jet-injection in Photodynamic Therapy for Basal Cell Carcinoma

Start date: September 9, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out whether injecting ALA into the skin with a jet-injection device and activating the drug with light is a safe treatment that causes few or mild side effects in people with basal cell carcinoma.